

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No. 8-17-01  
QUIG-100215  
AUG 08 2001  
TECH CENTER 1600-9900

In Re Application Of: **Richard ROSENBLOOM**


Serial No.  
09/847,121

Filing Date  
5/2/01

Examiner  
M. Bahar

Group Art. Unit  
1615

Title: **COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETIC NEUROPATHY**



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0462 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_) on \_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on Aug. 1, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Jianzhong Shen for  
Signature of Person Mailing Correspondence

**Kevin J. Dunleavy**

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

Jianzhong Shen for Reg. No. 48076  
Signature

Dated: August 1, 2001

Kevin J. Dunleavy, Esq.  
Registration No. 32,024  
KNOBLE & YOSHIDA, LLC  
Eight Penn Center, Suite 1350  
1628 John F. Kennedy Blvd.  
Philadelphia, PA 19103

CC:

1614

RECEIVED

TECH CENTER 1600 2900  
AUG 08 2001

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. QUIG-1002U
In Re Application Of: Richard ROSENBLOOM			
Serial No. 09/847,121	Filing Date 5/2/01	Examiner M. Bahar	Group And Unit 161
Title: COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETIC NEUROPATHY			
<div style="text-align: center;">Address to: Assistant Commissioner for Patents Washington, D.C. 20231</div> <div style="text-align: center;"><b>37 CFR 1.97(b)</b></div> <div>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.</div> <div style="text-align: center;"><b>37 CFR 1.97(c)</b></div> <div>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:<div style="margin-left: 40px;">1. a Final Action under 37 CFR 1.113, or</div><div style="margin-left: 40px;">2. a Notice of Allowance under 37 CFR 1.311,</div><div style="margin-left: 40px;">whichever occurs first.</div><div>Also submitted herewith is:</div><div style="margin-left: 40px;"><input type="checkbox"/> a certification as specified in 37 CFR 1.97(e);</div><div style="text-align: center; margin: 20px 0;"><b>OR</b></div><div style="margin-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).</div></div>			

